CD22 and acute lymphoblastic leukemia: In contrast, cytotoxic chemotherapy including inotuzumab ozogamicin, a cytotoxic CD22-targeting antibody drug conjugate used for treatment of R/R BCP ALL, has been shown to be myelosuppressive [32,33].